T. Rowe Price Investment Management Inc. Grows Holdings in Ascendis Pharma A/S $ASND

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Ascendis Pharma A/S by 12% during the 1st quarter, acquiring 328,278 additional shares and now owning 5.01% of the company valued at approximately $475.97 million.
• Ascendis Pharma A/S recently reported earnings of (-$0.93) EPS, exceeding analyst expectations, with revenue of $216.28 million, significantly above the consensus estimate.
• Multiple analysts have recently updated their price targets for Ascendis Pharma A/S, with the average target price set at $243.36 and a consensus rating of "Buy."

T. Rowe Price Investment Management Inc. lifted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 12.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,053,824 shares of the biotechnology company's stock after acquiring an additional 328,278 shares during the quarter. T. Rowe Price Investment Management Inc. owned approximately 5.01% of Ascendis Pharma A/S worth $475,970,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. RA Capital Management L.P. boosted its stake in shares of Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after buying an additional 402,316 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Ascendis Pharma A/S by 4.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after buying an additional 193,688 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Ascendis Pharma A/S by 7.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,283,207 shares of the biotechnology company's stock worth $314,330,000 after buying an additional 162,079 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Ascendis Pharma A/S by 0.6% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,877,917 shares of the biotechnology company's stock worth $292,692,000 after buying an additional 10,366 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Ascendis Pharma A/S by 3.7% in the 1st quarter. Invesco Ltd. now owns 1,198,478 shares of the biotechnology company's stock worth $186,795,000 after buying an additional 42,465 shares during the last quarter.

Ascendis Pharma A/S Stock Up 0.6%

NASDAQ:ASND traded up $1.2050 during mid-day trading on Monday, hitting $195.5050. 126,157 shares of the stock traded hands, compared to its average volume of 492,604. The business's 50-day moving average price is $178.20 and its 200 day moving average price is $163.98. The company has a market cap of $11.97 billion, a PE ratio of -37.65 and a beta of 0.41. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analysts' expectations of $163.17 million. Analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ASND has been the subject of several research analyst reports. Cantor Fitzgerald raised their price target on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Oppenheimer restated an "outperform" rating and set a $224.00 price target (up from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an "overweight" rating in a research note on Tuesday, August 19th. Fifteen analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $243.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.